Status:
NOT_YET_RECRUITING
Clinical Outcomes and Ejaculatory Function in BPO Patients Treated With Silodosin
Lead Sponsor:
Marmara University
Conditions:
Benign Prostate Obstruction (BPO)
Lower Urinary Tract Symptom
Eligibility:
MALE
40+ years
Brief Summary
This observational study aims to evaluate the relationship between silodosin-induced anejaculation and clinical outcomes in male patients with benign prostatic obstruction (BPO). Silodosin is a common...
Detailed Description
This is a observational study designed to investigate the association between silodosin-induced anejaculation and clinical outcomes in patients diagnosed with benign prostatic obstruction (BPO). Silod...
Eligibility Criteria
Inclusion
- Male patients aged 40 years or older
- Diagnosed with lower urinary tract symptoms (LUTS) due to benign prostatic obstruction (BPO)
- Initiating silodosin 8 mg/day therapy for the first time
- Able to complete IPSS and IIEF-5 questionnaires
- Willing and able to provide written informed consent
Exclusion
- History of prior treatment with silodosin or other α-blockers in the last 3 months
- Known neurogenic bladder or history of neurological disease affecting voiding
- History of prostate surgery or pelvic radiation
- Diagnosed prostate or bladder malignancy
- Use of medications affecting sexual function (e.g., PDE5 inhibitors) within the last month
- Severe cardiovascular, hepatic, or renal comorbidities
- Cognitive impairment preventing informed consent or questionnaire completion
Key Trial Info
Start Date :
June 15 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 12 2026
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT06989515
Start Date
June 15 2025
End Date
June 12 2026
Last Update
June 5 2025
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.